Want to see HK:1952 full AI Analyst Report?
1952 Stock Chart & Stats
HK$51.50
-HK$1.00(-2.24%)
At close: 4:00 PM EST
HK$51.50
-HK$1.00(-2.24%)
Day’s Range― - ―
52-Week RangeHK$22.70 - HK$75.15
Previous CloseN/A
Volume6.86M
Average Volume (3M)3.13M
Market Cap
HK$11.91B
Enterprise ValueHK$8.57K
Total Cash (Recent Filing)HK$2.73B
Total Debt (Recent Filing)HK$926.28M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Apr 01, 2027EPS Estimate
2.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding353,839,020
10 Day Avg. Volume4,149,807
30 Day Avg. Volume3,134,197
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)2.09
Price to Sales (P/S)6.51
P/FCF Ratio-64.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.73Price Target Upside-9.26% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.77
Revenue Forecast (FY)HK$3.25B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid revenue expansion indicates strong commercial adoption and improving market reach. If sustained, this growth can provide operating leverage and create a larger base from which Everest Medicines may eventually achieve profitability.
Healthy Gross MarginA roughly 60% gross margin suggests attractive product-level economics and potential pricing or portfolio strength. This provides a foundation for future operating leverage as revenue scales, provided development and commercial costs moderate.
Moderate Leverage And Sizable EquitySubstantial equity and moderate leverage give the company financial capacity to fund operations and growth. This balance-sheet cushion may reduce near-term refinancing pressure while management works toward sustainable profitability.
Bears Say
Persistent UnprofitabilityContinued operating and net losses show that rapid sales growth has not yet translated into sustainable earnings. Without further cost discipline or operating leverage, profitability may remain dependent on continued funding and balance-sheet resources.
Negative Free Cash FlowThe company is not yet self-funding, as operating and free cash flow remain negative despite meaningful improvement from 2024. Persistent cash burn could consume reserves and increase reliance on external financing if profitability is delayed.
Negative Returns On EquityNegative returns on equity indicate that shareholder capital has not yet generated positive earnings. If losses continue, accumulated capital may be progressively consumed, reducing financial flexibility and weakening the long-term investment case.
Everest Medicines Ltd. News
1952 FAQ
What was Everest Medicines Ltd.’s price range in the past 12 months?
Everest Medicines Ltd. lowest stock price was HK$22.70 and its highest was HK$75.15 in the past 12 months.
What is Everest Medicines Ltd.’s market cap?
Everest Medicines Ltd.’s market cap is HK$11.91B.
When is Everest Medicines Ltd.’s upcoming earnings report date?
Everest Medicines Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 222 days.
How were Everest Medicines Ltd.’s earnings last quarter?
Everest Medicines Ltd. released its earnings results on Aug 18, 2026. The company reported -HK$0.023 earnings per share for the quarter, beating the consensus estimate of -HK$1.085 by HK$1.062.
Is Everest Medicines Ltd. overvalued?
According to Wall Street analysts Everest Medicines Ltd.’s price is currently Overvalued.
Does Everest Medicines Ltd. pay dividends?
Everest Medicines Ltd. does not currently pay dividends.
What is Everest Medicines Ltd.’s EPS estimate?
Everest Medicines Ltd.’s EPS estimate is 2.17.
How many shares outstanding does Everest Medicines Ltd. have?
Everest Medicines Ltd. has 353,839,020 shares outstanding.
What happened to Everest Medicines Ltd.’s price movement after its last earnings report?
Everest Medicines Ltd. reported an EPS of -HK$0.023 in its last earnings report, beating expectations of -HK$1.085. Following the earnings report the stock price went down -18.716%.
Which hedge fund is a major shareholder of Everest Medicines Ltd.?
Currently, no hedge funds are holding shares in HK:1952
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Everest Medicines Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$46.73 (-9.26% Downside)
HK$46.73 (-9.26% Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
80.63%
Trailing 12-Months
Company Description
Everest Medicines Ltd.
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
1952 Stock 12 Month Forecast
Average Price Target
HK$46.73
▼(-9.26% Downside)
Technical Analysis
Zai Lab Ltd
―
Antengene Corporation Limited
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―